Middle East Partnership Advances Neurostimulation Care – February 18, 2026 | Mont-Saint-Guibert, Belgium Nyxoah has signed a Memorandum of Understanding with Sheikh Shakhbout Medical City to expand access to its Genio® hypoglossal nerve stimulation therapy for patients with Obstructive Sleep Apnea (OSA) across the Middle East. The collaboration is designed to strengthen therapy management programs, build clinical expertise, and accelerate regional adoption of the company’s neuromodulation-based treatment platform. The agreement reflects a strategic push to position Sheikh Shakhbout Medical City as a regional reference center for advanced OSA care, physician education, and scientific collaboration.
Science Significance
The Genio system represents a next-generation hypoglossal nerve stimulation therapy engineered to treat obstructive sleep apnea through targeted neuromodulation. Unlike traditional continuous positive airway pressure (CPAP) devices, the Genio platform is a leadless, battery-free implantable neurostimulation system designed to activate upper airway muscles during sleep, preventing airway collapse. The therapy reflects a broader scientific evolution toward implantable bioelectronic medicine, where neural pathways are modulated to treat chronic conditions. Clinical research has demonstrated improvements in apnea-hypopnea index scores and sleep quality outcomes, reinforcing neuromodulation as a viable alternative for patients intolerant to conventional therapies.
Regulatory Significance
From a regulatory standpoint, the Genio system has achieved multiple international milestones, including European CE Mark certification and U.S. FDA approval for select adult OSA patients. These approvals validate the device’s clinical safety, performance reliability, and manufacturing quality systems under regulated medical device frameworks. Expansion into Middle Eastern markets will require alignment with regional regulatory authorities, import licensing pathways, and post-market surveillance requirements. The MoU supports structured clinical deployment, ensuring adherence to device quality management systems, implant training protocols, and therapy monitoring standards as access expands.
Business Significance
Advertisement
Strategically, the partnership strengthens Nyxoah’s commercialization footprint in high-growth international markets. The Middle East represents a region with rising OSA prevalence and increasing investment in specialized sleep medicine infrastructure. By establishing Sheikh Shakhbout Medical City as a high-volume implant and training hub, Nyxoah aims to scale therapy adoption, physician familiarity, and referral networks. The collaboration also opens pathways for clinical research partnerships and regional reimbursement engagement, reinforcing the company’s long-term market access strategy.
Patients’ Significance
For patients living with moderate to severe obstructive sleep apnea, treatment adherence remains a major challenge, particularly among those unable to tolerate CPAP therapy. The Genio system offers a patient-centered, implantable alternative that supports natural breathing during sleep without external masks or airflow devices. Expanded regional access means eligible patients in the Middle East may benefit from improved sleep quality, reduced cardiovascular risk, and enhanced overall health outcomes associated with effective OSA management.
Policy Significance
The collaboration aligns with regional healthcare priorities focused on expanding access to advanced medical technologies and specialized treatment programs. Establishing a regional center of excellence supports clinical training, physician education, and innovation diffusion across healthcare systems. As sleep apnea is linked to chronic comorbidities such as metabolic and cardiovascular disease, improved therapy access may contribute to broader public health outcomes and healthcare system cost optimization.
Nyxoah’s partnership with Sheikh Shakhbout Medical City marks a significant step in advancing neuromodulation-based sleep apnea care across the Middle East. By combining clinical training, research collaboration, and patient access expansion, the initiative strengthens the regional adoption framework for implantable OSA therapies. As global demand for device-based respiratory treatments grows, such collaborations will play a central role in shaping the future landscape of sleep medicine innovation.
Source: Nyxoah SA press release
